NO307078B1 - Anvendelse av cholinesterase-inhibitorer for fremstilling av et farmasoeytisk akseptabelt preparat for behandling av tretthetssyndrom - Google Patents

Anvendelse av cholinesterase-inhibitorer for fremstilling av et farmasoeytisk akseptabelt preparat for behandling av tretthetssyndrom

Info

Publication number: NO307078B1
Authority: NO; Norway
Prior art keywords: pharmaceutically acceptable; treatment; cholinesterase; schizophrenia; benzodiazepines
Prior art date: 1991-05-14

Application number

NO934104A

Other languages

English (en)

Norwegian (no)

Other versions

NO934104D0 (no

NO934104L (no

Inventor

Ernir Snorrason

Original Assignee

Ernir Snorrason

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-05-14

Filing date

1993-11-12

Publication date

2000-02-07

1991-05-14 Priority claimed from IS3706A external-priority patent/IS3706A7/is

1992-02-13 Priority claimed from DK18192A external-priority patent/DK18192D0/da

1993-11-12 Application filed by Ernir Snorrason filed Critical Ernir Snorrason

1993-11-12 Publication of NO934104D0 publication Critical patent/NO934104D0/no

1993-11-12 Publication of NO934104L publication Critical patent/NO934104L/no

2000-02-07 Publication of NO307078B1 publication Critical patent/NO307078B1/no

Links

239000000544 cholinesterase inhibitor Substances 0.000 title abstract 3
206010016256 fatigue Diseases 0.000 title 1
238000004519 manufacturing process Methods 0.000 title 1
208000011580 syndromic disease Diseases 0.000 title 1
208000019901 Anxiety disease Diseases 0.000 abstract 3
229940049706 benzodiazepine Drugs 0.000 abstract 3
150000001557 benzodiazepines Chemical class 0.000 abstract 3
102100033639 Acetylcholinesterase Human genes 0.000 abstract 2
108010022752 Acetylcholinesterase Proteins 0.000 abstract 2
229940122041 Cholinesterase inhibitor Drugs 0.000 abstract 2
229940022698 acetylcholinesterase Drugs 0.000 abstract 2
230000003001 depressive effect Effects 0.000 abstract 2
201000010099 disease Diseases 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 abstract 2
230000000147 hypnotic effect Effects 0.000 abstract 2
229940002612 prodrug Drugs 0.000 abstract 2
239000000651 prodrug Substances 0.000 abstract 2
230000000241 respiratory effect Effects 0.000 abstract 2
208000022610 schizoaffective disease Diseases 0.000 abstract 2
201000000980 schizophrenia Diseases 0.000 abstract 2
239000000932 sedative agent Substances 0.000 abstract 2
230000001624 sedative effect Effects 0.000 abstract 2
VLGAHTYYCHWLNI-BHRZLAGCSA-N 1w4l Chemical compound O1C(=C23)C(OC)=CC=C2C=[N+](CCCCCCCCN2C(C4=CC=CC=C4C2=O)=O)CC[C@]23[C@@H]1C[C@@H](O)C=C2 VLGAHTYYCHWLNI-BHRZLAGCSA-N 0.000 abstract 1
HPOIPOPJGBKXIR-UHFFFAOYSA-N 3,6-dimethoxy-10-methyl-galantham-1-ene Natural products O1C(C(=CC=2)OC)=C3C=2CN(C)CCC23C1CC(OC)C=C2 HPOIPOPJGBKXIR-UHFFFAOYSA-N 0.000 abstract 1
108010053652 Butyrylcholinesterase Proteins 0.000 abstract 1
LPCKPBWOSNVCEL-UHFFFAOYSA-N Chlidanthine Natural products O1C(C(=CC=2)O)=C3C=2CN(C)CCC23C1CC(OC)C=C2 LPCKPBWOSNVCEL-UHFFFAOYSA-N 0.000 abstract 1
102100032404 Cholinesterase Human genes 0.000 abstract 1
208000007101 Muscle Cramp Diseases 0.000 abstract 1
102000019315 Nicotinic acetylcholine receptors Human genes 0.000 abstract 1
108050006807 Nicotinic acetylcholine receptors Proteins 0.000 abstract 1
206010033670 Panic reaction Diseases 0.000 abstract 1
208000028017 Psychotic disease Diseases 0.000 abstract 1
208000005392 Spasm Diseases 0.000 abstract 1
230000001773 anti-convulsant effect Effects 0.000 abstract 1
230000000561 anti-psychotic effect Effects 0.000 abstract 1
239000001961 anticonvulsive agent Substances 0.000 abstract 1
229960003965 antiepileptics Drugs 0.000 abstract 1
-1 antipsychotic Substances 0.000 abstract 1
230000036506 anxiety Effects 0.000 abstract 1
239000002249 anxiolytic agent Substances 0.000 abstract 1
230000000949 anxiolytic effect Effects 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
229960003980 galantamine Drugs 0.000 abstract 1
BGLNUNCBNALFOZ-WMLDXEAASA-N galanthamine Natural products COc1ccc2CCCC[C@@]34C=CCC[C@@H]3Oc1c24 BGLNUNCBNALFOZ-WMLDXEAASA-N 0.000 abstract 1
ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 abstract 1
208000013403 hyperactivity Diseases 0.000 abstract 1
230000002452 interceptive effect Effects 0.000 abstract 1
IYVSXSLYJLAZAT-NOLJZWGESA-N lycoramine Natural products CN1CC[C@@]23CC[C@H](O)C[C@@H]2Oc4cccc(C1)c34 IYVSXSLYJLAZAT-NOLJZWGESA-N 0.000 abstract 1
208000024714 major depressive disease Diseases 0.000 abstract 1
239000003158 myorelaxant agent Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Indole Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Transceivers (AREA)
Mobile Radio Communication Systems (AREA)

NO934104A 1991-05-14 1993-11-12 Anvendelse av cholinesterase-inhibitorer for fremstilling av et farmasoeytisk akseptabelt preparat for behandling av tretthetssyndrom NO307078B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
IS3706A IS3706A7 (is)	1991-05-14	1991-05-14	Notkun á galantamine-hydróbrómíði í geðlæknisfræði
DK18192A DK18192D0 (da)	1992-02-13	1992-02-13	Method of treating chronic fatigue syndrome
PCT/DK1992/000160 WO1992020327A1 (en)	1991-05-14	1992-05-14	Treatment of fatigue syndrome with cholinesterase inhibitors

Publications (3)

Publication Number	Publication Date
NO934104D0 NO934104D0 (no)	1993-11-12
NO934104L NO934104L (no)	1993-11-12
NO307078B1 true NO307078B1 (no)	2000-02-07

Family

ID=36886660

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO934104A NO307078B1 (no)	1991-05-14	1993-11-12	Anvendelse av cholinesterase-inhibitorer for fremstilling av et farmasoeytisk akseptabelt preparat for behandling av tretthetssyndrom

Country Status (13)

Country	Link
US (1)	US5312817A (de)
EP (2)	EP0584185B1 (de)
JP (1)	JP3291730B2 (de)
AT (1)	ATE183084T1 (de)
CA (1)	CA2108880A1 (de)
DE (1)	DE69229781T2 (de)
DK (1)	DK0584185T3 (de)
ES (1)	ES2134215T3 (de)
GR (1)	GR3031559T3 (de)
IE (1)	IE921547A1 (de)
NO (1)	NO307078B1 (de)
NZ (1)	NZ242744A (de)
WO (1)	WO1992020327A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0651746B1 (de) *	1992-07-24	2002-03-27	The Regents of the University of California	Arzneimittel, die den durch ampa rezeptoren vermittelten synaptischen respons erhöhen
DE4301782C1 (de) *	1993-01-23	1994-08-25	Lohmann Therapie Syst Lts	Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit
DE4301783C1 (de) *	1993-01-23	1994-02-03	Lohmann Therapie Syst Lts	Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil
US6316439B1 (en)	1993-10-15	2001-11-13	Aventis Pharamaceuticals Inc.	Galanthamine derivatives as acetylcholinesterase inhibitors
US6323196B1 (en) *	1993-10-15	2001-11-27	Aventis Pharmaceuticals Inc.	Galanthamine derivatives as acetylcholinesterase inhibitors
US6323195B1 (en) *	1993-10-15	2001-11-27	Aventis Pharmaceuticals Inc.	Galanthamine derivatives as acetylcholinesterase inhibitors
US5585375A (en) *	1994-07-01	1996-12-17	Davis; Bonnie M.	Method for alleviating jet lag
DE19509663A1 (de) *	1995-03-17	1996-09-19	Lohmann Therapie Syst Lts	Verfahren zur Isolierung von Galanthamin
DE19533772C1 (de) *	1995-09-12	1998-01-02	Hexal Ag	Tacrin/Selegilin-Pflaster
SE9504537D0 (sv) *	1995-12-19	1995-12-19	Jan Hedner	Sätt att behandla och diagnosticera andningsstörningar under sömn och medel för utförande av sättet
GB9606736D0 (en) *	1996-02-19	1996-06-05	Shire International Licensing	Therapeutic method
US5712259A (en) *	1996-04-22	1998-01-27	Birkmayer Pharmaceuticals	NADH and NADPH pharmaceuticals for treating chronic fatigue syndrome
TW506836B (en) *	1996-06-14	2002-10-21	Janssen Pharmaceutica Nv	Fast-dissolving galanthamine hydrobromide tablet
US6399622B1 (en)	1997-02-18	2002-06-04	A. Martin Lerner	Method for diagnosing and alleviating the symptoms of chronic fatigue syndrome
US6537997B1 (en)	1997-02-18	2003-03-25	A. Martin Lerner	Method for diagnosing and alleviating the symptoms of chronic fatigue syndrome
US5872123A (en) *	1997-02-18	1999-02-16	Lerner; A. Martin	Method for diagnosing and alleviating the symptoms of chronic fatigue syndrome
KR100648869B1 (ko) *	1998-09-30	2007-02-28	다케다 야쿠힌 고교 가부시키가이샤	방광 배출력 개선제
US20020177593A1 (en)	1998-09-30	2002-11-28	Yuji Ishihara	Agents and crystals for improving excretory potency of urinary bladder
PL348107A1 (en) *	1998-10-16	2002-05-06	Janssen Pharmaceutica Nv	Therapy for improving cognition
EE04996B1 (et)	1998-12-24	2008-04-15	Janssen Pharmaceutica N.V.	Reguleeritud vabanemisega galantamiinipreparaat, meetod selle valmistamiseks, seda sisaldav doseerimisvorm ning farmatseutiline pakend
EP1150695B1 (de) *	1999-01-11	2007-02-28	Atanas Russinov Djananov	Nahrungszusatz aus kräutern zur steigerung der muskulären kraft und ausdauer von athleten
US8603546B2 (en) *	1999-01-11	2013-12-10	Herbaceuticals Inc.	Herbal supplement for increased muscle strength and endurance for athletes
EP2311463A1 (de)	1999-12-10	2011-04-20	Bonnie M. Davis	Analoga des galanthamins und lycoramins als modulatoren von nikotinrezeptoren
CA2310950C (en) *	2000-04-03	2005-11-08	Janssen Pharmaceutica N.V.	An efficacious dosage regiment of galantamine that reduces side effects
US6825177B2 (en) *	2000-10-30	2004-11-30	Parker Hughes Institute	Aryl phosphate derivatives of d4T with potent anti-viral activity
AU2004216360B2 (en) *	2003-02-27	2009-09-17	Eisai R & D Management Co., Ltd.	Pharmaceutical composition for treatment of drug dependence
WO2005016327A2 (en) *	2003-08-13	2005-02-24	Janssen Pharmaceutica, N.V.	Treatment of sleep disorders with cholinesterase inhibitors
US20050143350A1 (en) *	2003-11-19	2005-06-30	Seed John C.	Combination drug therapy to treat obesity
DE10354894A1 (de) *	2003-11-24	2005-07-07	Hf Arzneimittelforschung Gmbh	Orale Formulierungen des Desoxypeganins und deren Anwendungen
WO2006040688A2 (en)	2004-10-12	2006-04-20	Ernir Snorrason	Inhibitors of acetylcholinesterase for treating skin diseases
US20090253654A1 (en)	2005-09-22	2009-10-08	Galantos Pharma Gmbh	Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
EP1777222A1 (de)	2005-09-22	2007-04-25	Galantos Pharma GmbH	Cholinesterase Inhibitoren mit erhöter Blut Hirn Schranke Permeabilität zur Behandlung von kognitiven Störungen
JP5230613B2 (ja)	2006-05-23	2013-07-10	テラコス・インコーポレイテッド	グルコース輸送体阻害剤およびその使用方法
US8748419B2 (en)	2006-06-16	2014-06-10	Theracos, Inc.	Treating obesity with muscarinic receptor M1 antagonists
US7893053B2 (en)	2006-06-16	2011-02-22	Theracos, Inc.	Treating psychological conditions using muscarinic receptor M1 antagonists
BRPI0809607A2 (pt)	2007-04-02	2014-09-30	Theracos Inc	Composto, composição farmacêutica, combinação farmacêutica, e, método para tratar uma doença
MX2010002027A (es)	2007-08-23	2010-03-15	Theracos Inc	Derivados de bencilbenceno y metodos de uso.
AU2009270936B2 (en)	2008-07-15	2014-12-18	Theracos, Inc.	Deuterated benzylbenzene derivatives and methods of use
MX2011001855A (es)	2008-08-22	2011-03-24	Theracos Inc	Procesos para la preparacion de inhibidores de sglt2.
CA2744498C (en)	2008-11-25	2017-10-24	University Of Rochester	Mlk inhibitors and methods of use
US20120129838A1 (en) *	2009-04-24	2012-05-24	The Industry & Academic Cooperation In Chungnam National University	Composition for Preventing and Treating Alopecia Disorder Containing Morgalanthamine Compounds as an Active Ingredient
ES2332645B1 (es) *	2009-06-30	2010-10-18	Grifols, S.A.	Utilizacion de alfa-1-antitripsina para la preparacion de medicamentos para el tratamiento del sindrome de fatiga cronica.
AU2011258465B2 (en)	2010-05-24	2016-12-15	University Of Rochester	Bicyclic heteroaryl kinase inhibitors and methods of use
WO2011153712A1 (en)	2010-06-12	2011-12-15	Theracos, Inc.	Crystalline form of benzylbenzene sglt2 inhibitor
JP6133790B2 (ja)	2011-02-18	2017-05-24	ザスクリプスリサーチインスティテュート	ミエリン形成細胞運命へのオリゴデンドロサイト前駆細胞の定方向分化
US8524664B2 (en)	2011-06-02	2013-09-03	Colorado Seminary, Which owns and Operates The Univeristy of Denver	Methods of treating overproduction of cortisol using ACTH antagonist peptides
US20140100238A1 (en)	2012-10-04	2014-04-10	Ohio State University	Method of diagnosing and treating epstein barr virus-based myalgic encephalomyelitis chronic fatigue syndrome patients
EP2925319B1 (de)	2012-11-30	2019-01-09	University Of Rochester	Mixed-lineage-kinaseinhibitoren für hiv/aids-therapien

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3221827A1 (de) *	1982-06-09	1983-12-15	DSO Pharmachim, Sofija	Biostimulierendes mittel
US4663318A (en) *	1986-01-15	1987-05-05	Bonnie Davis	Method of treating Alzheimer's disease
EP0363415B1 (de) *	1987-05-04	2008-10-15	Davis, Bonnie	Mittel zur behandlung der alzheimer-krankheit

1992
- 1992-05-14 EP EP92910754A patent/EP0584185B1/de not_active Expired - Lifetime
- 1992-05-14 JP JP50977792A patent/JP3291730B2/ja not_active Expired - Fee Related
- 1992-05-14 US US07/883,038 patent/US5312817A/en not_active Expired - Lifetime
- 1992-05-14 WO PCT/DK1992/000160 patent/WO1992020327A1/en not_active Ceased
- 1992-05-14 EP EP19920610034 patent/EP0515301A3/en active Pending
- 1992-05-14 AT AT92910754T patent/ATE183084T1/de not_active IP Right Cessation
- 1992-05-14 ES ES92910754T patent/ES2134215T3/es not_active Expired - Lifetime
- 1992-05-14 CA CA002108880A patent/CA2108880A1/en not_active Abandoned
- 1992-05-14 DE DE69229781T patent/DE69229781T2/de not_active Expired - Fee Related
- 1992-05-14 DK DK92910754T patent/DK0584185T3/da active
- 1992-05-14 NZ NZ242744A patent/NZ242744A/en not_active IP Right Cessation
- 1992-07-01 IE IE154792A patent/IE921547A1/en not_active IP Right Cessation
1993
- 1993-11-12 NO NO934104A patent/NO307078B1/no not_active Application Discontinuation
1999
- 1999-10-15 GR GR990402653T patent/GR3031559T3/el unknown

Also Published As

Publication number	Publication date
NO934104D0 (no)	1993-11-12
ATE183084T1 (de)	1999-08-15
DE69229781T2 (de)	2000-01-05
NO934104L (no)	1993-11-12
DE69229781D1 (de)	1999-09-16
DK0584185T3 (da)	2000-02-07
JP3291730B2 (ja)	2002-06-10
CA2108880A1 (en)	1992-11-15
EP0515301A2 (de)	1992-11-25
EP0584185A1 (de)	1994-03-02
EP0584185B1 (de)	1999-08-11
ES2134215T3 (es)	1999-10-01
EP0515301A3 (en)	1993-06-16
GR3031559T3 (en)	2000-01-31
WO1992020327A1 (en)	1992-11-26
AU1886392A (en)	1992-12-30
NZ242744A (en)	1997-02-24
JPH06507617A (ja)	1994-09-01
IE921547A1 (en)	1992-11-18
US5312817A (en)	1994-05-17
AU658424B2 (en)	1995-04-13

Legal Events

Date	Code	Title	Description
2008-01-14	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO307078B1 (no)	2000-02-07	Anvendelse av cholinesterase-inhibitorer for fremstilling av et farmasoeytisk akseptabelt preparat for behandling av tretthetssyndrom
IS3863A (is)	1992-11-15	Meðferð þreytueinkenna
Mokrov et al.	2015	Design, synthesis and anxiolytic-like activity of 1-arylpyrrolo [1, 2-a] pyrazine-3-carboxamides
ATE412415T1 (de)	2008-11-15	Inhibitoren der phosphodiesterase der zyklischen nucleotiden, mit einer benzodiazepinischen struktur, und deren verwendung in therapie
MY140557A (en)	2009-12-31	Pyrazolopyrimidines and pyrrolopyrimidines for treatment of neuronal and other disorders
ATE229530T1 (de)	2002-12-15	Tetrahydropyridin-(oder 4-hydroxypiperidin) alkylazole mit sigma und/oder 5ht 1a-rezeptor aktivität
Chrovian et al.	2016	Novel phenyl-substituted 5, 6-dihydro-[1, 2, 4] triazolo [4, 3-a] pyrazine P2X7 antagonists with robust target engagement in rat brain
AR028475A1 (es)	2003-05-14	Derivados de azaindol y uso de los mismos para la manufactura de un medicamento para el tratamiento de la depresion.
WO2004011464A3 (fr)	2004-08-26	Nouvelles pyrazolo[1,5-a]-1,3,5-triazines substituees et leurs analogiques, compositions pharmaceutiques les contenant, utilisation a titre de medicament et procedes pour leur preparation
Grahame et al.	2001	Alcohol place preference conditioning in high-and low-alcohol preferring selected lines of mice
PT1023291E (pt)	2004-09-30	Derivados de dipiridoimidazole uteis no tratamento de desordens do sistema nervoso central
Gemma et al.	2011	Synthesis and antiplasmodial activity of bicyclic dioxanes as simplified dihydroplakortin analogues
PL376368A1 (en)	2005-12-27	4-aminopiperidine derivatives, processes for their preparation and their use as medicaments
Zhu et al.	1998	Synthesis of 2, 6, 7-Trichloro-1-(β-d-ribofuranosyl) naphtho [2, 3-d] imidazole: A Linear Dimensional Analogue of the Antiviral Agent TCRB
NO20021041L (no)	2002-04-03	Polymorfismer av N-metyl-N-(3{3-[2-tienylkarbonyl]pyrazol- [1,5-alfa]-pyrimidin-7-yl}fenyl)acetamid og blandinger ogfremgangsmåter relatert dertil
AR024963A1 (es)	2002-10-30	Oxazincarbazoles en el tratamiento de enfermedades del snc
Houlihan et al.	1985	Sleep-inducing N-alkyl-5-[m-(trifluoromethyl) phenyl]-5-hydroxy-2-pyrrolidinones and N-alkyl-3-(trifluoromethyl) cinnamamides
Ochiai et al.	2004	Orally active PDE4 inhibitors with therapeutic potential
ATE112256T1 (de)	1994-10-15	9-amino-2-phenylbicyclo(3.3.1>nonane und 9-amino- 2-phenylbicyclo(3.3.1>-non-2-ene und diese enthaltende therapeutische mittel.
Stemmelin et al.	2005	A76A THE α7nACh RECEPTOR AGONIST, SSR180711, DISPLAYS ANTIDEPRESSANT-LIKE EFFECTS IN RODENTS
DK0399653T3 (da)	1994-11-14	Triazolo(4,5-c)pyridinderivater med antikrampe virkning